---
title: Omnicef Antibiotic Overview & Definition for Clinicians
date: '2026-06-14'
slug: omnicef-antibiotic-overview-definition-for-clinicians
description: Learn the Omnicef antibiotic overview and definition, dosing guidelines,
  safety profile, and guideline‑based uses for clinicians.
updated: '2026-06-14'
image: https://images.unsplash.com/photo-1706204787318-d7de50772977?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=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&ixlib=rb-4.1.0&q=80&w=400
author: Dr. Benjamin Paul
site: Rounds AI
---

# Omnicef Antibiotic Overview & Definition for Clinicians

## Why Omnicef Matters and Common Confusion Among Clinicians

Omnicef (cefdinir) is a third‑generation oral cephalosporin. It is approved for community infections such as acute otitis media, sinusitis, pharyngitis, and uncomplicated skin infections ([Mayo Clinic](https://www.mayoclinic.org/drugs-supplements/cefdinir-oral-route/description/drg-20073288)). Clinicians frequently confuse its antimicrobial spectrum and dosing with other oral cephalosporins. That confusion can lead to suboptimal drug selection or dosing errors ([ID Stewardship](https://www.idstewardship.com/third-generation-oral-cephalosporin-best-cefdinir-cefpodoxime/)). Cefdinir offers broader gram‑negative coverage than many first‑generation agents but has limited activity against Pseudomonas, a nuance sometimes overlooked ([StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK551517/)).

Understanding why clinicians need an Omnicef overview and common misconceptions helps reduce prescribing errors and saves time. Clinicians using Rounds AI experience faster access to cited guidance at the point of care to support verification before acting. Rounds AI is available on the web and iOS, with conversation history synced across devices on the Monthly plan (and Enterprise). Rounds AI's evidence‑first approach complements clinical judgment without replacing it. Rounds AI is built with a HIPAA‑aware design, delivers citation‑first answers, and includes a 3‑day free trial to make evaluation straightforward. Learn more about Rounds AI's approach to evidence‑linked clinical answers for point‑of‑care reference.

## Core Definition and Classification of Omnicef

**Omnicef (cefdinir)** is the brand name for cefdinir, an oral third‑generation cephalosporin antibiotic used in outpatient practice. According to prescribing information, its FDA‑approved indications—presented by adult and pediatric groups—include the following: in adults, community‑acquired pneumonia, acute bacterial sinusitis, pharyngitis/tonsillitis, and uncomplicated skin and skin‑structure infections; in pediatric patients (6 months of age and older), acute bacterial otitis media, pharyngitis/tonsillitis, acute bacterial sinusitis, community‑acquired pneumonia, and uncomplicated skin and skin‑structure infections ([FDA Omnicef Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf)). Uncomplicated urinary tract infection is not an FDA‑approved indication for Omnicef. As a third‑generation agent, cefdinir is a semi‑synthetic β‑lactam with a molecular formula of C14H13N5O5S2 and a molecular weight of approximately 395.4 g/mol ([DrugBank](https://go.drugbank.com/drugs/DB01153)). Third‑generation cephalosporins generally provide expanded Gram‑negative coverage and relatively reduced Gram‑positive activity compared with first‑ and second‑generation agents, a distinction that informs empirical selection in many clinical scenarios ([StatPearls – Cephalosporins Chapter](https://www.ncbi.nlm.nih.gov/books/NBK551517/)). Efficacy data cited in the FDA label report clinical cure rates in adults of about 85–90% for cefdinir 300 mg once daily given for 10 days in acute bacterial sinusitis pivotal trials ([FDA Omnicef Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf)). Pharmacokinetic summaries note oral bioavailability near 16–22% after a single 300 mg dose, a property relevant to absorption and dose planning ([StatPearls – Cephalosporins Chapter](https://www.ncbi.nlm.nih.gov/books/NBK551517/)). For clinicians, a concise, citation‑linked definition like this supports rapid verification during rounds or pre‑charting.

> Rounds AI helps clinicians access such evidence‑linked drug summaries at the point of care, pairing concise definitions with source material you can open and review; Rounds AI links directly to FDA labeling to reduce indication creep and off‑label errors and surfaces reliable reference chemistry data with citations. Teams using Rounds AI can streamline literature checks and guideline confirmation when evaluating antibiotics like Omnicef. Learn more about Rounds AI’s approach to evidence‑linked clinical answers and how it supports point‑of‑care verification for drug information.

## Omnicef Dosing Guidelines for Adults and Children

Omnicef (cefdinir) dosing depends on age, weight, renal function, and the infection being treated. The FDA‑approved adult regimen is 300 mg orally every 12 hours, or 600 mg once daily, for many indications ([FDA Omnicef label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf)). Typical treatment duration varies by diagnosis; courses often run 5–10 days for common community infections ([Mayo Clinic](https://www.mayoclinic.org/drugs-supplements/cefdinir-oral-route/description/drg-20073288)).

Pediatric dosing is weight‑based and capped to avoid excessive single doses.

- **Adults:** 300 mg PO q12h or 600 mg PO daily.
- **Children (≥6 mo):** 14 mg/kg/day divided q12h, max 600 mg.
- **Renal impairment (CrCl <30 mL/min):** 300 mg daily.

Some references present these dosing patterns and the single‑dose ceiling ([Drugs.com dosing guide](https://www.drugs.com/dosage/omnicef.html)). When calculating pediatric doses, confirm the weight and round to available formulations. Clinicians using Rounds AI can quickly verify these pediatric dosing ranges and caps with direct FDA and pediatric references at the point of care.

Renal impairment requires dose reduction when creatinine clearance falls below 30 mL/min. For adults with CrCl <30 mL/min, limit therapy to 300 mg once daily per the product label. For children with significant renal impairment, dosing is typically adjusted to a once‑daily schedule (for example, 7 mg/kg once daily); confirm exact pediatric renal adjustments on the FDA label or pediatric guidance ([Drugs.com dosing guide](https://www.drugs.com/dosage/omnicef.html)). Rounds AI cites the FDA label directly for renal adjustments, supporting rapid verification. Adjustments reduce accumulation and potential adverse effects.

For bedside decision making, remember the single‑dose ceiling differs by age: adults may receive a single 600 mg dose, while pediatric single doses are typically capped at 300 mg. Duration should reflect the infection and local guidance; otitis media and pneumonia often require longer courses than uncomplicated pharyngitis ([Mayo Clinic](https://www.mayoclinic.org/drugs-supplements/cefdinir-oral-route/description/drg-20073288)). Clinicians using Rounds AI can quickly surface these dosing ranges and verify sources at the point of care. To explore how evidence‑linked Q&A supports dosing checks and renal adjustments, learn more about Rounds AI’s approach to clinical reference and verification.

## Pharmacology and Mechanism of Action

### Renal Dosing Adjustments

For adults with creatinine clearance (CrCl) below 30 mL/min, limit cefdinir to 300 mg per day. Recommended dosing options include:

- 300 mg once daily
- 150 mg twice daily

These limits are noted in dosing references and the FDA label ([Drugs.com Omnicef Dosage Guide](https://www.drugs.com/dosage/omnicef.html), [FDA prescribing information](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021675)).

Pediatric patients with reduced renal function should receive 7 mg/kg once daily, not to exceed 300 mg total ([Drugs.com Omnicef Dosage Guide](https://www.drugs.com/dosage/omnicef.html); [FDA prescribing information](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021675)).

Elderly patients may accumulate cefdinir when kidney function declines. Age-based dosing data are limited, so monitor renal function and adjust dosing accordingly. Renal clearance correlates with creatinine clearance, and roughly 60% of a dose is excreted unchanged in urine per the FDA label ([FDA prescribing information](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021675)).

Clinicians using Rounds AI can quickly access evidence-linked dosing references to confirm adjustments at the point of care. Rounds AI's emphasis on guideline and label citations supports institutional review and cautious practice. Learn more about Rounds AI's approach to evidence-linked dosing guidance.

## Clinical Indications, Guideline Recommendations, and Use Cases

Cefdinir (Omnicef) is a third‑generation oral cephalosporin with bactericidal activity. It works by binding penicillin‑binding proteins and inhibiting peptidoglycan cross‑linking, which disrupts cell‑wall synthesis and leads to bacterial lysis ([FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216755Orig1s001lbl.pdf), [DrugBank](https://go.drugbank.com/drugs/DB00535)). The mechanism explains activity against common respiratory and skin pathogens targeted by this class.

Key pharmacokinetic parameters inform dosing choices. Oral bioavailability is approximately 16–25%, supporting oral therapy when appropriate ([DailyMed](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c3705f2-0b44-4d38-a7f9-4b392d0a1a45), [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216755Orig1s001lbl.pdf)). Time to peak concentration (Tmax) is about 2–3 hours. Reported half‑life is near 1.7 hours in adults, which influences dosing frequency. Protein binding is low to moderate, and distribution favors extracellular fluids ([FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216755Orig1s001lbl.pdf)).

Elimination occurs predominantly via the kidneys, with roughly 18% of the administered dose recovered unchanged in urine (reported range ~12–23%), so renal function drives clearance ([DailyMed](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2c3705f2-0b44-4d38-a7f9-4b392d0a1a45), [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216755Orig1s001lbl.pdf)). Consequently, dose reductions or interval adjustments are needed for reduced creatinine clearance to avoid accumulation. Clinicians should integrate PK/PD characteristics with patient renal function when selecting dose and duration. Rounds AI displays concise PK summaries with clickable citations to support bedside confirmation.

The FDA label lists cefdinir (Omnicef) indications for common outpatient bacterial infections. Approved uses include acute bacterial sinusitis, otitis media, and streptococcal pharyngitis. The label also covers uncomplicated skin and soft‑tissue infections and uncomplicated urinary tract infections for patients aged six months and older ([FDA Omnicef Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf)).

Major guideline groups generally treat cefdinir as an alternative, not a first‑line choice. The IDSA 2012 acute bacterial rhinosinusitis (ABRS) guideline favors amoxicillin‑based therapy first‑line; cefdinir is an option mainly for beta‑lactam allergy or intolerance ([IDSA 2012 ABRS Guideline](https://academic.oup.com/cid/article/54/8/e72/286507)). The American Academy of Pediatrics lists cefdinir among oral options for otitis media when first‑line agents are unsuitable ([AAP Cefdinir Monograph (2024)](https://publications.aap.org/pediatriccare/drug-monograph/18/5225/Cefdinir)). For community‑acquired pneumonia, the ATS/IDSA 2019 guideline does not list cefdinir as a preferred oral agent for typical adult outpatient regimens ([ATS/IDSA 2019 CAP Guideline](https://www.idsociety.org/practice-guideline/community-acquired-pneumonia/)).

Cefdinir is clinically useful when oral third‑generation cephalosporin coverage is needed and first‑line agents are unsuitable. It is a reasonable choice for many patients with penicillin allergy who require outpatient oral therapy. Comparative evidence and guideline statements generally favor first‑generation cephalosporins (for example, cephalexin) over cefdinir for many uncomplicated skin‑and‑soft‑tissue infections; clinicians should interpret those findings in the context of infection severity, local susceptibility, and patient factors ([IDSA 2014 SSTI Guideline](https://academic.oup.com/cid/article/59/2/e10/310813)). Rounds AI retrieves and cites the latest guideline recommendations and primary sources to inform first‑line versus alternative choices.

At the point of care, clinicians using Rounds AI can quickly pull guideline‑aligned summaries and linked prescribing information to verify when cefdinir fits a case. Rounds AI helps teams compare guideline recommendations and primary sources before selecting an alternative agent. For any patient, confirm indications and specific prescribing details against the FDA label and current guidelines before prescribing.

#

Clinicians can ask an evidence‑focused clinical knowledge assistant a question such as "Omnicef dosing for a 12‑year‑old with otitis media". They receive a concise, sourced response with inline references. Rounds AI returns answers that cite primary references clinicians can open at the bedside. Those citations link to FDA labeling and pediatric guidance. Examples include the [FDA Omnicef Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf) and the [AAP Cefdinir Monograph (2024)](https://publications.aap.org/pediatriccare/drug-monograph/18/5225/Cefdinir).

Access on web and iOS supports point‑of‑care use and synced Q&A history across devices. Teams using Rounds AI experience faster verification without sacrificing clinical judgment. Learn more about Rounds AI's approach to evidence‑linked medication reference for clinical leaders evaluating point‑of‑care tools.

Omnicef (cefdinir) is an oral third‑generation cephalosporin commonly used for selected respiratory and skin infections. Typical adult regimens include 300 mg twice daily or 600 mg once daily, according to clinical references and the drug label ([Mayo Clinic – Cefdinir Overview](https://www.mayoclinic.org/drugs-supplements/cefdinir-oral-route/description/drg-20073288); [FDA Omnicef Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s021lbl.pdf)). Reduce dose or extend the dosing interval in severe renal impairment and consult the full FDA labeling for specific creatinine‑clearance guidance. Use Omnicef where guideline‑directed therapy supports a third‑generation oral cephalosporin, and always confirm pediatric dosing, allergy history, and drug interactions before prescribing.

To verify dosing and open source citations at the point of care, consider Rounds AI as an evidence‑linked clinical reference. Clinical leaders and frontline clinicians can learn more about Rounds AI's approach to providing cited clinical answers for rapid, verifiable decision support.